GenSight Biologics (EPA:SIGHT) said today that the first person was treated in a first-in-man trial evaluating GenSight’s gene therapy candidate, GS030-DP, in combination with a wearable optronic visual stimulation device, GS030-MD.
Scientists are evaluating the drug-device combination in 18 people with retinitis pigmentosa.
Get the full story at our sister site, Drug Delivery Business News.
The post GenSight Biologics launches trial for gene therapy, eye device combo appeared first on MassDevice.
from MassDevice https://ift.tt/2SjVmxf
Cap comentari:
Publica un comentari a l'entrada